La Roche-sur-Foron (FR)
{name}
{subtitle}
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~16 mi. (Pringy, France, +137 more cities)
facility
Centre Hospitalier Annecy Genevois ( Site 0361)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~16 mi. (Genève, Switzerland, +145 more cities)
facility
Hopitaux Universitaires de Geneve HUG ( Site 1706)
condition
Non-Small Cell Lung Carcinoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~16 mi. (Genève, Switzerland, +105 more cities)
facility
Hopitaux Universitaires de Geneve HUG. ( Site 1406)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib
drug type
targeted therapy
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
city
~16 mi. (Genève, Switzerland, +34 more cities)
facility
Hôpitaux Universitaires de Genève (HUG) ( Site 0335)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~18 mi. (Metz-Tessy, France, +158 more cities)
facility
Centre Hospitalier Annecy Genevois ( Site 0811)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~46 mi. (Lausanne, Switzerland, +199 more cities)
facility
CHUV (centre hospitalier universitaire vaudois) ( Site 0712)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
city
~46 mi. (Lausanne, Switzerland, +21 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)
condition
Melanoma
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
city
~46 mi. (Lausanne, Switzerland, +27 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)
condition
Melanoma
drug
lenvatinib, +3 more drugs
drug type
immunotherapy, +1 more type
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
city
~46 mi. (Lausanne, Switzerland, +30 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)
condition
Melanoma
drug
lenvatinib, +4 more drugs
drug type
immunotherapy, +2 more types